Key Developments: Bio-Rad Laboratories Inc (BIO)

BIO on New York Consolidated

117.76USD
21 Jul 2014
Price Change (% chg)

$-0.50 (-0.42%)
Prev Close
$118.26
Open
$117.88
Day's High
$118.36
Day's Low
$117.39
Volume
44,710
Avg. Vol
70,775
52-wk High
$134.13
52-wk Low
$113.02

Search Stocks

Latest Key Developments (Source: Significant Developments)

Bio-Rad Laboratories Inc acquires GnuBIO and DNA sequencing technology
Thursday, 10 Apr 2014 08:00pm EDT 

Bio-Rad Laboratories Inc:Announced that it has purchased GnuBIO, Inc.Terms of the transaction were not disclosed.  Full Article

Bio-Rad Laboratories Inc lowers FY 2013 revenue guidance - Conference Call
Thursday, 7 Nov 2013 05:00pm EST 

Bio-Rad Laboratories Inc:Says FY 2013 it guided currency-neutral revenue growth to be in the 3% to 3.5% range for the base business, and 3.5% to 4% including Serotec.Says it also told that any further deterioration in Europe, or funding in the academic and government research markets, could make goals difficult to achieve.Says given year-to-date currency-neutral growth of about 2% for the base business, and 3.1% including Serotec, and combined with the continued European challenges and constrained funding environment.Says it now believe FY 2013 currency-neutral sales growth will likely remain in that same 2% to 3% range it has experienced so far this year.Says it reported revenue of $2.069 billion in fiscal 2012.FY 2013 revenue of $2.139 billion - Thomson Reuters I/B/E/S Estimates.  Full Article

Bio-Rad Laboratories Inc Announces Appointment Of Auditor-Form 8-K
Wednesday, 9 Oct 2013 04:42pm EDT 

Bio-Rad Laboratories Inc reported in its Form 8-K that on October 8, 2013, Bio-Rad Laboratories, Inc. (Company) engaged KPMG LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2013 based on the recommendation and authorization of the Audit Committee of its Board of Directors.  Full Article

Bio-Rad Laboratories Inc Reaffirms FY 2013 Revenue Guidance-Conference Call
Tuesday, 6 Aug 2013 05:00pm EDT 

Bio-Rad Laboratories Inc announced that for fiscal 2013, it remain cautiously optimistic of achieving the currency-neutral sales growth guidance of 3% to 3.5% for the base business it provided last February as well as expectation of a 3.5% to 4% topline growth when including the Serotec sales. The Company reported revenue of $2.069 billion in fiscal 2012. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $2.149 billion for fiscal 2013.  Full Article

Bio-Rad Laboratories Inc Reaffirms FY 2013 Revenue Guidance-Conference Call
Tuesday, 7 May 2013 05:00pm EDT 

Bio-Rad Laboratories Inc announced that for fiscal 2013, the Company is cautiously optimistic of achieving a currency-neutral sales growth guidance of 3% to 3.5% for the base business that the Company provided in February. The Company reported revenue of $2.069 billion in fiscal 2012. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $2.15 billion for fiscal 2013.  Full Article

Bio-Rad Laboratories Inc Issues FY 2013 Revenue Guidance Above Analysts' Estimates-Conference Call
Tuesday, 26 Feb 2013 10:00pm EST 

Bio-Rad Laboratories Inc announced that for fiscal 2013, it expects currency neutral sales growth to be in the 3% to 3.5%. The Company reported revenue of $2.069 billion in fiscal 2012. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $2.12 billion for fiscal 2013.  Full Article

Bio-Rad Laboratories Inc Acquires AbD Serotec, Division Of MorphoSys AG
Thursday, 10 Jan 2013 09:05am EST 

Bio-Rad Laboratories Inc announced that it has purchased AbD Serotec, a division of MorphoSys AG, for approximately 53 million euros in cash. AbD Serotec is one of the antibody manufacturers offering over 15,000 antibodies, kits, and accessories. AbD Serotec has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom, as well as other facilities in Germany and the U.S.  Full Article

Bio-Rad Laboratories Inc Signs Definitive Agreement to Acquire AbD Serotec from MorphoSys AG
Sunday, 16 Dec 2012 01:41pm EST 

Bio-Rad Laboratories Inc announced that it has signed a definitive agreement to acquire AbD Serotec, a division of MorphoSys AG for EUR53 million in cash. The transaction is subject to certain closing conditions and is expected to be completed in January.  Full Article

Circadian Technologies Ltd Enters Into License Agreement With Bio-Rad Laboratories, Inc.
Wednesday, 14 Nov 2012 05:30pm EST 

Circadian Technologies Ltd announced that its wholly owned subsidiary, Vegenics Pty Ltd, has entered into a non-exclusive worldwide license agreement with one of the providers of life science research and clinical diagnostics products, Bio-Rad Laboratories, Inc., (NYSE: BIO and BIOb), to market research assays for the detection of VEGF-C and/or VEGF-D in biological fluids.  Full Article

Bio-Rad Laboratories Inc Lowers FY 2012 Revenue Guidance-Conference Call
Tuesday, 6 Nov 2012 10:00pm EST 

Bio-Rad Laboratories Inc announced that in the last call it has guided currency neutral revenue growth to be at the low end of 3.5% to 4.5% range for fiscal 2012. Given year to date currency neutral growth of about 2.7% and combined with the continued economic challenges, especially in the European region, it now believe the full year currency neutral sales growth for fiscal 2012 will likely remain in that same 2.5% to 3% range have experienced so far this year. The Company reported revenue of $2.074 billion in fiscal 2011.  Full Article

CORRECTED-U.S. CDC recommends combo HIV test for faster detection of virus

(Corrects in paragraph 3 to show company making recommended test is Bio-Rad Laboratories, not Alere Inc)

Search Stocks